Join
Live feed
·
PRReleasevia Quantisnow
Caribou Biosciences Inc. logo

Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy

ByQuantisnow·Wall Street's wire, on your screen.
CRBU· Caribou Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track CRBU (Caribou Biosciences Inc.) and more on Quantisnow.